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Effectiveness of artemether-lumefantrine
provided by community health workers in underfive children with uncomplicated malaria in rural
Tanzania: an open label prospective study
Billy E Ngasala1,2*, Maja Malmberg1, Anja M Carlsson1, Pedro E Ferreira1,7, Max G Petzold3,4, Daniel Blessborn5,6,
Yngve Bergqvist5,6, José P Gil1,7,8, Zul Premji2, Andreas Mårtensson1,3

Abstract
Background: Home-management of malaria (HMM) strategy improves early access of anti-malarial medicines to
high-risk groups in remote areas of sub-Saharan Africa. However, limited data are available on the effectiveness of
using artemisinin-based combination therapy (ACT) within the HMM strategy. The aim of this study was to assess
the effectiveness of artemether-lumefantrine (AL), presently the most favoured ACT in Africa, in under-five children
with uncomplicated Plasmodium falciparum malaria in Tanzania, when provided by community health workers
(CHWs) and administered unsupervised by parents or guardians at home.
Methods: An open label, single arm prospective study was conducted in two rural villages with high malaria
transmission in Kibaha District, Tanzania. Children presenting to CHWs with uncomplicated fever and a positive
rapid malaria diagnostic test (RDT) were provisionally enrolled and provided AL for unsupervised treatment at
home. Patients with microscopy confirmed P. falciparum parasitaemia were definitely enrolled and reviewed weekly
by the CHWs during 42 days. Primary outcome measure was PCR corrected parasitological cure rate by day 42, as
estimated by Kaplan-Meier survival analysis. This trial is registered with ClinicalTrials.gov, number NCT00454961.
Results: A total of 244 febrile children were enrolled between March-August 2007. Two patients were lost to
follow up on day 14, and one patient withdrew consent on day 21. Some 141/241 (58.5%) patients had recurrent
infection during follow-up, of whom 14 had recrudescence. The PCR corrected cure rate by day 42 was 93.0% (95%
CI 88.3%-95.9%). The median lumefantrine concentration was statistically significantly lower in patients with
recrudescence (97 ng/mL [IQR 0-234]; n = 10) compared with reinfections (205 ng/mL [114-390]; n = 92), or no
parasite reappearance (217 [121-374] ng/mL; n = 70; p ≤ 0.046).
Conclusions: Provision of AL by CHWs for unsupervised malaria treatment at home was highly effective, which
provides evidence base for scaling-up implementation of HMM with AL in Tanzania.

Background
Malaria still causes significant morbidity and mortality,
primarily among under-five children in sub-Saharan
Africa[1]. Access to prompt, effective malaria treatment
within 24 hours of the onset of symptoms is critical to prevent mortality and reduce morbidity[2]. However, access
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to effective anti-malarial medicines and other preventive
interventions is limited especially in remote rural areas of
sub-Saharan Africa [3-5]. To improve early access of effective anti-malarial treatment, the World Health Organization (WHO) is promoting home-based management of
malaria (HMM) [5]. This strategy involves training of
community health workers (CHWs) to manage malarial
illness; access to effective, pre-packed anti-malarial medicines; an effective communication strategy; and good
mechanism for supervision and monitoring [2]. Previous

© 2011 Ngasala et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.

Ngasala et al. Malaria Journal 2011, 10:64
http://www.malariajournal.com/content/10/1/64

studies have demonstrated that prompt and effective treatment of uncomplicated malaria with chloroquine at community level significantly reduced malaria-related
morbidity and mortality [6-8].
Due to widespread resistance to chloroquine and sulphadoxine/pyrimethamine, most malaria-endemic countries in Africa and Asia have adopted the WHO
recommendation of introducing artemisinin-based combination therapy (ACT) as first-line treatment for
uncomplicated Plasmodium falciparum malaria [9]. Artemether-lumefantrine (AL) is presently the most widely
adopted ACT in Africa, including Tanzania [10].
Although AL has a relatively complex treatment regimen,
i.e. twice daily for 3 days, data from sub-Saharan Africa
at health facility level indicate that AL is highly effective
even with unsupervised administration [11-14]. Moreover, recent studies have shown that ACT can be successfully integrated into the HMM strategy[15-17]. These
studies indicate that CHWs can safely dispense ACT
with suggestible good adherence by caregivers to the correct treatment schedules. However, concerns remain
among researchers and policy-makers due to limited data
on the effectiveness of using ACT in the HMM strategy
[18,19]. Another concern is that widespread presumptive
use of ACT may spur development of parasite tolerance/
resistance to these precious medicines[20].
To improve targeting of ACT to malaria infected patients
parasitological confirmation is essential at community level
in remote areas of sub-Saharan Africa, where a majority of
fever patients seek care. Antigen-based rapid malaria diagnostic tests (RDTs) may represent an important tool to
improve the diagnostic efficiency if incorporated in the
HMM strategy, considering that they are easy to use and
interpret and do neither require access to skilled technicians nor electricity. Previous studies have shown that
RDTs can be accurately used by CHWs [21,22]. Recent
community-based studies in Tanzania and Ethiopia have
shown that the use of RDTs by CHWs improved targeting
of AL to malaria infected patients [17,23].
This study reports data on polymerase chain reaction
(PCR) corrected effectiveness of AL, when provided at
community level by CHWs and used unsupervised by
parents or guardians at home for treatment of uncomplicated P. falciparum malaria in under-five children,
during an extended follow-up period of 42 days, adherence to treatment by measuring lumefantrine concentrations on day 7 after initiation of treatment, and possible
selection of genetic markers associated with AL tolerance/resistance.

Methods
Study sites

The study was conducted between March-August 2007
in two neighbouring villages, Ngeta and Mwanabwito, in
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rural Kibaha District, located about 50 km west of Dar
es Salaam, Tanzania. These two villages, with a total
population of 4,500 people, were among five villages
involved in a previous assessment of RDT use by CHWs
to improve targeting of ACT at the community level
[17]. The study sites were purposely selected based on
presence of active CHWs, accessibility during rainy season, and within three hours drive by car from Muhimbili University of Health and Allied Sciences (MUHAS),
Dar es Salaam. Malaria transmission is high, with peaks
related to the rainy seasons in May-July and DecemberJanuary. Plasmodium falciparum is the dominant parasite species. There is one dispensary in each village and
most referrals are sent to Mlandizi Health Centre, situated at a distance of 9 to 10 kms from the selected villages. AL was the first-line treatment for uncomplicated
malaria at the time of the trial.
Selection and training of CHWs

After consultations with dispensary staff and village leaders, six CHWs were selected among the existing 40
CHWs in the two villages. The selection of study CHWs
was based on gender balance, residential area and ability
to keep records. A three-day training workshop was
conducted at each village dispensary. The CHWs were
trained on how to recognize symptoms of both uncomplicated and severe malaria, as well as other febrile
childhood non-malaria diseases, such as pneumonia
(cough with fast breathing) and acute diarrhoea, as well
as in administration of AL and how to educate caregivers on the use of AL. The CHWs were also trained
on how to perform and interpret RDT, i.e. Paracheck
Pf®, according to the manufacturer’s instructions (Paracheck Pf, Orchid Biomedical Systems, Goa, India) and
simplified pictorial instructions (RDT job aid); prepare
thick blood smears and blood spots on filter paper
(Whatman 3MM) from finger prick blood samples; and
filling of case record forms. Each CHW was provided
with a weighing scale, a digital thermometer, pre-packed
AL tablets, paracetamol tablets, a dosing chart for AL,
RDTs, RDT job aid and a storage iron box. The CHWs
were responsible for referral of patients and storage of
the study drugs and other supplies for the study. During
the study period each CHW was given a monthly allowance equivalent to 25 USD.
Patients

Children presenting to CHWs with symptoms suggestive
of uncomplicated malaria were screened for study eligibility. Patients were enrolled if they met the following
inclusion criteria: age of 3-59 month; body weight of ≥5
kg; fever (≥ 37.5°C axillary) or a history of fever in the
preceding 24 hours; P. falciparum malaria confirmed by
RDT and later by microscopy; able to ingest tablets
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orally; able to attend stipulated follow-up visits; provision of written informed consent by a parent or guardian, and absence of any general danger signs of severe
disease (convulsions, lethargic/unconscious, unable to
drink/breast feed, vomiting everything). Patients with
negative RDT test results and/or signs of severe disease
were to be immediately referred to the village dispensary
for further management.
Study design, treatments and procedures

This was an open label, single arm prospective study,
assessing PCR corrected parasitological cure rate of a
six-dose treatment with unsupervised intake of AL provided by CHWs to under-five children with uncomplicated P. falciparum infection with an extended followup of 42 days. Patients fulfilling the inclusion criteria
were provisionally enrolled based on a positive RDT
result and provided AL treatment in standard doses
according to the body weight: one tablet per dose for
patients weighing 5-14.9 kg (yellow blister pack) and
two per dose for 15-24 kg (blue blister pack). Every blister pack had pictures showing how the drug should be
given. The first dose was given under supervision of the
CHWs. If patients vomited the first dose within 30 min;
administration of the full dose was repeated. The other
five doses were given by the parents/caregivers at home.
Standardized verbal instructions on dose, frequency and
advice to combine treatment with fatty meals or breast
milk were given by CHWs. Paracetamol was provided to
all febrile patients. Parents or guardians were instructed
to report to the CHWs or the village dispensary if the
child’s condition had not improved after 48 hours or if
worsened at any time. Anti-malarial medicines and
other drugs in the study were provided by the research
project free-of-charge.
Blood smears were stained with Giemsa and read at
the Department of Parasitology, MUHAS. The results
were provided to the CHWs and patients within three
days of sampling. Children with positive RDTs but negative blood smear results were excluded from the study
and referred to the dispensary. Children with microscopically confirmed malaria were definitely enrolled. Parents or guardians were requested to bring their children
back to the CHWs on days 7, 14, 21, 28, 35 and 42 or
on any day that they felt ill. At each visit, children were
assessed for symptoms, possible adverse events, and
body temperature. Finger prick blood samples were collected for microscopy (thick blood smears) and PCR
analysis (on Whatman filter paper), respectively, at day
of enrolment and at each follow-up visit. In addition,
the research team leader collected blood samples (100
μl taken by capillary tube) on pre-treated filter papers
on day 7, which were used later for determination of
lumefantrine blood concentrations. If patients did not
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return for scheduled follow-up visits, they were actively
followed-up in their homes the next day.
Patients with recurrent infections within 14 days after
initiation of AL treatment and in children who developed symptoms or signs of severe malaria during follow-up were withdrawn from the study, and referred to
the village dispensary or Mlandizi health centre for rescue treatment with quinine. In children with clinical
failure (non-severe malaria) after day 14 or parasitological failure day 42 after the initial therapy were retreated
with AL in accordance with national guidelines [24].
Laboratory procedures
Microscopy

All thick blood smears were picked up from CHWs by
the research team within 24 hours after collection and
stained with 5% Giemsa for 20 minutes at MUHAS.
Two qualified microscopists independently read all thick
blood smears. The parasite density was estimated by
counting the number of asexual parasites per 200 (for
gametocytes 1,000) white blood cells and calculating
parasites per μL, assuming a white blood cell count of
8,000 per μL. A smear was declared negative if no asexual parasites were seen after examining 200 high power
fields. Disagreement in readings (positive versus negative) or an at least two fold difference in parasite density, a third decisive microscopy reading, again blinded
was to be done.
Molecular analysis

Distinction between recrudescence and reinfection
events was performed by the use of stepwise genotyping
of the P. falciparum genes merozoite surface protein-2
(msp2), glutamate-rich protein (glurp) and msp1 using
standard protocols [25]. Recrudescences were defined as
samples containing at least one matching allelic band in
all markers, from paired samples collected on day of
enrolment (D0) and day of recurrent infection (R0). A
reinfection was defined as the absence of any matching
allelic band in at least one marker in the paired blood
samples.
Single nucleotide polymorphisms (SNPs) in the P. falciparum chloroquine resistance transporter gene (pfcrt)
K76T and P. falciparum multidrug resistance gene 1
(pfmdr1) N86Y, previously associated with quinoline
resistance, were analysed according to established ApoI
restriction enzyme-based PCR restriction fragment
length polymorphism (PCR-RFLP) protocols [26].
Determination of blood lumefantrine concentrations

Capillary blood samples (100 μL, taken by heparinized
micropipette) were applied on filter papers pre-treated
with 0.75 M tartaric acid. These blood samples were
dried, put in small zipped plastic bags and frozen at -20°
C the day after sampling. After completion of the field
trial they were transported to the Bioanalytics and
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Pharmacokinetics laboratory of Dalarna University, Sweden, where lumefantrine blood concentrations were
measured by solid-phase extraction and liquid chromatography [27].
Outcome measures

The day-42 PCR corrected parasitological cure rate was the
primary efficacy outcome, i.e. proportion of patients with
clearance of asexual parasitaemia within seven days of
initiation of treatment, without recrudescence within 42
days after initiation of treatment, and without use of rescue
medication for clinical signs of malaria. Secondary outcomes included PCR corrected parasitological cure rates
on days 14 and 28 after treatment; risk of reinfections after
treatment; day 7 blood lumefantrine concentrations; selection of genetic markers (SNPs) in pfcrt and pfmdr1; and
adverse events defined as signs and symptoms that
occurred or increased in severity after treatment started.
Statistical analysis

Assuming that AL treatment provided by CHWs would
result in less than 85% PCR corrected parasitological
cure rate by day 42. According to the WHO protocol
[28], with an estimated treatment failure lower than
15%, confidence interval of 95%, a precision of 10% and
a 20% drop out rate, the minimum sample size needed
was at least 60 patients. To compare effectiveness data
from this study with both efficacy and effectiveness data
from a separate study conducted at health facility level
[29], a total of 200 under-five children were recruited.
Data were double-entered and validated using EpiData
software, version 3.02 (EpiData Association, Odense
Denmark) and analysis was performed using Stata 10.0
(StataCorp, College Station, Texas, USA). Proportions
were compared with X 2 test or Fisher’s exact test as
appropriate. All patients with microscopically confirmed
P. falciparum malaria who had taken at least one full
dose of the study medication and had at least one postbaseline efficacy assessment were included in the analyses. Cure rates and cumulative proportion of recurrent
parasitaemia were estimated by Kaplan-Meier survival
analysis. Data were censored for patients who were lost
to follow-up or for patients with reinfections, and indeterminate or missing PCR results at the last day seen.
Ethical clearance

The study was approved by the National Institute for
Medical Research in Tanzania and Regional Ethics Committee Stockholm, Sweden, and was registered with
identifier NCT00454961[30]. Before enrolment, written
informed consent was obtained from the parents or
legal guardians of the children.
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Results
Between March and July 2007, 398 febrile children were
screened for study eligibility, 300 (75.4%) were provisionally enrolled based on a positive RDT, of whom 250
(83.3%) were P. falciparum positive by microscopy (Figure 1). Of these 250 patients, 244 (97.6%) met the inclusion criteria and were thus definitely enrolled (Figure 1).
Three children (<2%) did not complete the 42-day follow-up period (Figure 1); one due to withdrawn consent
on day 21 and two children moved from the study area
on day 14. Baseline demographic characteristics are
shown in Table 1. A majority of patients, 216/244
(88.5%), had parasite density ≥2,000/μL blood, and one
child had parasite density >200,000/μL, but had no general danger signs indicating severe disease.
Effectiveness assessment

No early treatment failure was reported. On day 7, all
patients were afebrile, but 7/244 (2.9%) were still parasitaemic. PCR analysis of these seven patients revealed
four reinfections, two recrudescences and one indeterminate result. By day 42, some 141/241 (58.5%) patients
had recurrent parasitaemia (Figure 2), of whom 32
(22.7%) presented with fever. Parasite genotyping
showed that 118 (84%) were due to reinfection, 14
(10%) recrudescence and 9 (6%) indeterminate results.
The PCR corrected cure rates at days 14, 28 and 42
were 97.9%, 95.1% and 93.0%, respectively (Table 2).
There was no statistically significant difference in median (range) time to recrudescent infections, i.e. 21 (7-42)
days compared to 28 (7-42) days for reinfections (p =
0.41). Three (21%) of the 14 children with recrudescent
infection were identified after 28 days of follow-up. At
baseline, eight patients carried gametocytes (Table 1).
During follow-up only one gametocyte carrier was
observed on day 7.
Day 7 lumefantrine concentrations

A total of 177 of 244 (73%) patients had blood lumefantrine concentrations measured on day 7 after initiation
of treatment. The median (range) lumefantrine concentration on day 7 was 205 ng/mL (0-1887). The median
lumefantrine concentration was significantly lower in
patients with recrudescence (97 ng/mL [IQR 0-234]; n =
10) than in those with reinfections (205 ng/mL [114390]; n = 92), or no parasite reappearance (217 [121374] ng/mL; n = 70; p ≤ 0.046) (Figure 3). Overall, 63%
(112/177) of patients had lumefantrine concentrations
<280 ng/mL[31]. Of the 10 patients with recrudescent
infections analysed, eight had lumefantrine concentrations <280 ng/mL. All seven patients with parasitaemia
on day 7 had lumefantrine concentration <280 ng/mL.
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Figure 1 Flow of the patients through the study.

Pfmdr1 N86Y and pfcrt K76T SNPs

Proportions of parasites carrying pfmdr1 N86 and pfcrt
K76 at baseline and recurrent parasitemia are presented
in Table 3. The pfmdr1 86N allele was observed to be
selected among recurrent infections (p < 0.01), while the
pfcrt K76T SNP did not show any pattern of selection
upon AL administration.
Adverse events

AL was well tolerated. No deaths occurred. Two serious
adverse events were reported, both were due to severe
Table 1 Baseline demographic characteristics
Characteristic

(N = 244)

Male

131 (53.7%)

Age, median months (range)
Weight, median kg (range)

31.3 (6.0-62.0)
11.7 (6.0-23.0)

Number of children weighing 5-<15 kg

190 (77.9%)

Number of children weighing 15-<25 kg

54 (22.1%)

Asexual parasitaemia, geometric mean parasite/μl
(range),

19054 (400240000)

Number of patients with parasite density ≥ 2000/μl

216 (88.5%)

Temperature, °C, mean

38.0

Gametocyte carriage

8 (3.3%)

Vomiting on day 0

89 (36.5%)

malaria on days 14 and 42. In total 162 adverse events
(mild or moderate in severity) were reported during follow-up, the most common being fever (34%), cough
(34%) and diarrhoea (12%). These events were considered unrelated to AL treatment.

Discussion
The results from this study showed that intake of unsupervised AL used in HMM was highly effective and
well-tolerated for the treatment of acute uncomplicated
P. falciparum malaria in Tanzanian children below five
years of age. This study is the first to assess the PCR
corrected cure rate achieved with ACT in the context of
HMM after an extended follow-up to 42 days. A previous multicentre study showed high effectiveness of
ACT used in HMM [19]. However, this study had only
28 days follow-up. Importantly, the results are consistent
with previous effectiveness studies conducted at health
facility level in sub-Saharan Africa [11-14].
However, a concern is the limited post-treatment prophylactic effect of AL in this high malaria transmission
area, which resulted in more than half of the patients having recurrent infections within the 42-day follow-up period. A great majority of all recurrent infections were due
to reinfections, when assessed with stepwise genotyping

Page 6 of 10





FXPXODWLYHSURSRUWLRQ






Ngasala et al. Malaria Journal 2011, 10:64
http://www.malariajournal.com/content/10/1/64








)ROORZXSWLPH GD\V





















1XPEHUDWULVN



Figure 2 Kaplan Meier curve showing cumulative proportion of children with recurrent parasitaemia during follow-up after
artemether-lumefantrine treatment.

using three polymorphic genetic markers. Young children
with little or no immunity to malaria may have a shorter
post-treatment prophylactic effect compared to older children and adults [32]. Similar high risk of recurrent infections after AL treatment has been reported in other high
transmission areas in sub-Saharan Africa [33-36]. This
highlights the need of integrated approaches for malaria
control. Recent data indicate that the use of ACT, supported by vector control interventions including long-lasting insecticide-treated nets (LLINs) significantly reduced
malaria-associated morbidity and mortality in seven
malaria-endemic countries, including Zanzibar islands in
Tanzania [37].
Adherence to AL treatment in this trial was assessed
by measuring day 7 lumefantrine levels, a potentially
Table 2 PCR uncorrected and corrected cure rates as
estimated by Kaplain-Meier analysis
Cure rate

rate, % (95%CI)

Day 14 PCR uncorrected

91.8 (87.5-94.6)

Day 14 PCR corrected

97.9 (95.1-99.1)

Day 28 PCR uncorrected

60.2 (53.7-66.1)

Day 28 PCR corrected

95.1 (91.4-97.3)

Day 42 PCR uncorrected

41.5 (35.3-47.7)

Day 42 PCR corrected

93.0 (88.3-95.9)

more reliable method of measuring adherence to treatment than the use of questionnaires, which has a potential for recall bias [38,39]. The method applied in this
study has shown adequate sensitivity for quantification
of lumefantrine from capillary blood samples collected
on pre-treated filter paper[27]. Its minimal invasiveness
and overall simple sampling procedure makes it a feasible field method in clinical trials conducted in remote
areas. The observed median day 7 lumefantrine concentration of 205 ng/mL was similar to the concentrations
achieved with unsupervised intake of AL in two recent
health facility based studies conducted in the neighbouring Bagamoyo District and Malawi[29,38]. Moreover, the
proportion of children (over 60%) that had a day 7
lumefantrine concentration <280 ng/mL, a cut-off level
previously associated with increased risk of treatment
failure [31], was similar to unsupervised groups at the
health facility based studies [11,40]. The absorption of
lumefantrine is known to have a high variability and
suboptimal drug levels could potentially result from
inadequate fat intake [11,40]. Although, in this study, fat
intake was not assessed, caregivers were encouraged to
accompany each AL dose with milk or fat-containing
food. Low blood lumefantrine concentrations increase
the risk of treatment failure and reinfections [40-43]. In
this study all recrudescent infections and reinfections
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Figure 3 Box plots of day 7 lumefantrine concentrations versus endpoints after treatment with artemether-lumefantrine.

identified on day 7 occurred in patients with lumefantrine concentration <280 ng/mL. Similarly, a majority of
patients with recrudescent infections during the 42 days
follow-up had day 7 blood lumefantrine concentration
<280 ng/mL. To improve adherence to unsupervised AL
treatment therefore represents a key challenge for
malaria control programmes in Africa to reduce the risk
of adverse treatment outcome in children with uncomplicated malaria infection.

In high transmission areas, residual low/sub-therapeutic concentrations of the long acting partner drug in
ACT create strong selective pressure for development
and spread of tolerant/resistant parasites [44,45]. In this
study, similarly to previous observations, there was significant selection of the pfmdr1 N86 allele in recurrent
infections after AL treatment [46-50]. This data further
support the potential importance of this gene in parasite
response to this ACT. Less clear is the involvement of

Table 3 Frequencies of the analyzed single-nucleotide polymorphism (SNPs), before treatment (D0) and in recurrent
infections after treatment with artemether-lumefantrine (R0)
Frequencies, (pure+mix)/total*, % (95%CI)
pfmdr1 N86

pfcrt K76

D0
All patients

(115+56)/234

73.1 (67.4-78.8)a

(152+41)/232

83.2 (78.3-88.0)

Patients with recrudescence during follow-up

(5+8)/13

100.0 (100.0-100.0)

(7+5)/13

92.3 (75.6-100.0)

Patients with reinfection during follow-up

(53+33)/115

74.8 (66.7-82.8)b

(71+23)/113

83.2 (76.2-90.2)

All patients

(99+30)/138

93.5 (89.3-97.7)a

(92+15)/126

84.9 (78.6-91.3)

Patients with recrudescence

(12+2)/14

100.0 (100.0-100.0)

(9+2)/13

84.6 (61.9-100.0)

Patients with new infection

(79+25)/112

92.9 (88.0-97.7)b

(74+13)/104

83.7 (76.4-90.9)

R0

* denotes the total no of successful analyses; CI, confidence interval.
* denotes the total no of successful analyses; CI, confidence interval.
a
Statistically significant increase between baseline and all recurrent infections, P < 0.0001.
b
Statistically significant increase between baseline and only reinfections, P = 0002.
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the pfcrt K76T SNP - in contrast to a recent study conducted in Bagamoyo District, Tanzania [46], a significant
selection of the pfcrt K76 allele in recurrent infections
after AL treatment was not observed. This might be due
to lack of statistical power of the present study, taking
in account the high baseline prevalence of the pfcrt K76
(> 80%). It can also reflect that although the potential of
pfcrt K76T to modulate is by now well supported in
vitro [46,51], its in vivo importance might be less general than the observed for pfmdr1 86N, being more
dependent on the overall genetic makeup of the studied
parasite populations.
Selecting study sites that were geographically accessible within three hours by car from Dar es Salaam might
have introduced a selection bias. However, the selected
villages were not different from those not included in
the study in terms of number and quality of CHWs.
Moreover, the weekly follow-up and supervision by
researchers may have influenced the behaviour of
CHWs and caregivers and resulted in improved adherence, however, supervision and monitoring of the community activities is one of the key components of the
HMM strategy.

Conclusions
In conclusion, this study showed high PCR corrected
effectiveness of AL used in HMM during an extended
follow-up of 42 days, which provides evidence for scaling-up implementation of HMM strategy with AL in
Tanzania. However, the risk of recurrent infections after
AL treatment was high, why integration of ACT with
preventive interventions is critical for improved malaria
control. The in vivo selection of genetic markers associated with drug resistance confirms that AL is vulnerable to selection of resistance-related polymorphisms in
areas of high malaria transmission. It is crucial that the
HMM strategy incorporates components for monitoring
adherence to ACT treatment and drug resistance.
Acknowledgements
The authors thank the community health workers, children and their parents
who took part in it. The cooperation of health workers at Ngeta and
Mwanabwito dispensaries is highly appreciated. The study was financed by
SIDA in the framework of a collaborative Malaria Project between Muhimbili
University of Health and Allied Sciences and Karolinska Institutet.
Author details
1
Malaria Research, Infectious Diseases Unit, Department of Medicine Solna,
Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
2
Department of Parasitology, Muhimbili University of Health and Allied
Sciences, Dar es Salaam, Tanzania. 3Division of Global Health IHCAR,
Department of Public Health Sciences, Karolinska Institutet, Stockholm,
Sweden. 4Nordic School of Public Health, Gothenburg, Sweden. 5Dalarna
University College, Borlänge, Sweden. 6Department of Physical and Analytical
Chemistry, Uppsala University, Uppsala, Sweden. 7Centre of Molecular and
Structural Biomedicine, Institute for Biophysics and Biotechnology, University
of Algarve, Gambelas, Portugal. 8Laboratory of Molecular Anthropology and

Page 8 of 10

Health, Department of Anthropolgy, Binghamton University, Binghamton, NY
13902-6000, USA.
Authors’ contributions
BEN, ZP and AM conceived and designed the study and contributed to
implementation of field study. BEN and ZP supervised the field work. MM,
AMC, PEF and JPG performed molecular analyses, DB and YB performed
drug level analysis. BEN and MGP analysed data. BEN and AM wrote the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 August 2010 Accepted: 16 March 2011
Published: 16 March 2011
References
1. World Health Organization: WHO/HTM/GMP/2008.1. World Malaria Report
2008 [http://www.who.int/malaria/wmr2008/malaria2008.pdf].
2. World Health Organization: WHO/HTM/MAL/2005.1101. The roll back
malaria strategy for improving access to treatment through home
management of malaria [http://www.who.int/malaria/publications/atoz/
who_htm_mal_2005_1101/en/index.html].
3. Roll Back Malaria Partnership: The Global Malaria Action Plan 2008 [http://
rbm.who.int/gmap/gmap.pdf].
4. The Millennium Development Goals Report 2008. [http://mdgs.un.org/
unsd/mdg/Resources/Static/Products/Progress2008/MDG_Report_2008_En.
pdf].
5. WHO: World Health Organization/Special Programme for Research and
Training in Tropical Diseases, WHO/HTM/MAL/2004.1096; TDR/IDE/HMM/
04.1. Scaling-up Home-based Management of Malaria.From Research to
Implementation [http://whqlibdoc.who.int/hq/2004/
WHO_HTM_MAL_2004.1096.pdf].
6. Pagnoni F, Convelbo N, Tiendrebeogo J, Cousens S, Esposito F: A
community-based programme to provide prompt and adequate
treatment of presumptive malaria in children. Trans R Soc Trop Med Hyg
1997, 91:512-517.
7. Sirima SB, Konate A, Tiono AB, Convelbo N, Cousens S, Pagnoni F: Early
treatment of childhood fevers with pre-packaged antimalarial drugs in
the home reduces severe malaria morbidity in Burkina Faso. Trop Med Int
Health 2003, 8:133-139.
8. Kidane G, Morrow RH: Teaching mothers to provide home treatment of
malaria in Tigray, Ethiopia: a randomised trial. Lancet 2000, 356:550-555.
9. WHO: Guidelines for the treatment of malaria, second edition [http://www.
who.int/malaria/publications/atoz/9789241547925/en/index.html].
10. Global AMDP database - WHO African region. [http://www.who.int/
malaria/am_drug_policies_by_region_afro/en/].
11. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J,
Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F,
Guthmann JP: Supervised versus unsupervised intake of six-dose
artemether-lumefantrine for treatment of acute, uncomplicated
Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.
Lancet 2005, 365:1467-1473.
12. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C,
Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine
+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemetherlumefantrine for outpatient treatment of malaria in Tanzanian children:
a four-arm randomised effectiveness trial. Lancet 2005, 365:1474-1480.
13. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B,
Houze P, Kossou H, Amedome H, Massougbodji A, Cot M, Deloron P:
Comparison of sulfadoxine-pyrimethamine, unsupervised artemetherlumefantrine, and unsupervised artesunate-amodiaquine fixed-dose
formulation for uncomplicated Plasmodium falciparum malaria in Benin:
a randomized effectiveness noninferiority trial. J Infect Dis 2009,
200:57-65.
14. Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangen F, Kamya MR,
Dorsey G, D’Alessandro U, Rosenthal PJ, Talisuna AO: Effectiveness of
quinine versus artemether-lumefantrine for treating uncomplicated
falciparum malaria in Ugandan children: randomised trial. BMJ 2009, 339:
b2763.

Ngasala et al. Malaria Journal 2011, 10:64
http://www.malariajournal.com/content/10/1/64

15. Ajayi IO, Browne EN, Garshong B, Bateganya F, Yusuf B, Agyei-Baffour P,
Doamekpor L, Balyeku A, Munguti K, Cousens S, Pagnoni F: Feasibility and
acceptability of artemisinin-based combination therapy for the home
management of malaria in four African sites. Malar J 2008, 7:6.
16. Chinbuah AM, Gyapong JO, Pagnoni F, Wellington EK, Gyapong M:
Feasibility and acceptability of the use of artemether-lumefantrine in
the home management of uncomplicated malaria in children 6-59
months old in Ghana. Trop Med Int Health 2006, 11:1003-1016.
17. Mubi M, Janson A, Warsame M, Mårtensson A, Källander K, Petzold MG,
Ngasala B, Maganga G, Gustafsson LL, Massele A, Tomson G, Premji Z,
Björkman A: malaria rapid testing by community health workers is
effective and safe for targeting malaria treatment: randomised crossover trial in Tanzania. PLoS One 2011.
18. Hopkins H, Talisuna A, Whitty CJ, Staedke SG: Impact of home-based
management of malaria on health outcomes in Africa: a systematic
review of the evidence. Malar J 2007, 6:134.
19. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO, Gbotosho GO,
Yusuf B, Boateng S, Mugittu K, Cousens S, Nanyunja M, Pagnoni F:
Effectiveness of artemisinin-based combination therapy used in the
context of home management of malaria: a report from three study
sites in sub-Saharan Africa. Malar J 2008, 7:190.
20. Talisuna AO, Bloland P, D’Alessandro U: History, dynamics, and public
health importance of malaria parasite resistance. Clin Microbiol Rev 2004,
17:235-254.
21. Premji Z, Minjas JN, Shiff CJ: Laboratory diagnosis of malaria by village
health workers using the rapid manual ParaSight-F test. Trans R Soc Trop
Med Hyg 1994, 88:418.
22. Cho Min N, Gatton ML: Performance appraisal of rapid on-site malaria
diagnosis (ICT malaria Pf/Pv test) in relation to human resources at
village level in Myanmar. Acta Trop 2002, 81:13-19.
23. Barnes KI, Chanda P, Ab Barnabas G: Impact of the large-scale deployment
of artemether/lumefantrine on the malaria disease burden in Africa: case
studies of South Africa, Zambia and Ethiopia. Malar J 2009, 8(Suppl 1):S8.
24. Tanzania NMCP, (ed): National guidelines for malaria diagnosis and
treatment. Dar es Salaam; 2006.
25. Snounou G: Genotyping of Plasmodium spp. Nested PCR. Methods Mol
Med 2002, 72:103-116.
26. Veiga MI, Ferreira PE, Bjorkman A, Gil JP: Multiplex PCR-RFLP methods for
pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol Cell
Probes 2006, 20:100-104.
27. Blessborn D, Romsing S, Annerberg A, Sundquist D, Bjorkman A,
Lindegardh N, Bergqvist Y: Development and validation of an automated
solid-phase extraction and liquid chromatographic method for
determination of lumefantrine in capillary blood on sampling paper. J
Pharm Biomed Anal 2007, 45:282-287.
28. WHO: WHO/HTM/RBM/2003.50. Assessment and monitoring of antimalarial
drug efficacy for the treatment of uncomplicated falciparum malaria [http://
www.who.int/malaria/publications/atoz/whohtmrbm200350/en/].
29. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D,
Bergqvist Y, Gil JP, Premji Z, Bjorkman A, Martensson A: Efficacy and
effectiveness of artemether-lumefantrine after initial and repeated
treatment in children < 5 years of age with acute uncomplicated
Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin
Infect Dis 2011.
30. ClinicalTrial.gov. [http://www.ClinicalTrials.gov].
31. Ezzet F, Mull R, Karbwang J: Population pharmacokinetics and therapeutic
response of CGP 56697 (artemether + benflumetol) in malaria patients.
Br J Clin Pharmacol 1998, 46:553-561.
32. White NJ: How antimalarial drug resistance affects post-treatment
prophylaxis. Malar J 2008, 7:9.
33. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB,
Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG: Artemisinin
combination therapies for treatment of uncomplicated malaria in
Uganda. PLoS Clin Trials 2006, 1:e7.
34. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG,
Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F,
Dorsey G: Artemether-lumefantrine versus dihydroartemisininpiperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials
2007, 2:e20.

Page 9 of 10

35. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ,
Ouedraogo JB: Randomized comparison of amodiaquine plus
sulfadoxine-pyrimethamine, artemether-lumefantrine, and
dihydroartemisinin-piperaquine for the treatment of uncomplicated
Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007,
45:1453-1461.
36. Martensson A, Ngasala B, Ursing J, Isabel Veiga M, Wiklund L, Membi C,
Montgomery SM, Premji Z, Farnert A, Bjorkman A: Influence of
consecutive-day blood sampling on polymerase chain reaction-adjusted
parasitological cure rates in an antimalarial-drug trial conducted in
Tanzania. J Infect Dis 2007, 195:597-601.
37. WHO: World Malaria Report 2008. WHO/HTM/GMP/2008.1 World Health
Organization;[http://www.who.int/malaria/wmr2008/malaria2008.pdf].
38. Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P,
Hughes DA, Molyneux ME, Ward SA, Winstanley PA, Lalloo DG:
Measurement of adherence, drug concentrations and the effectiveness
of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxinepyrimethamine in the treatment of uncomplicated malaria in Malawi.
Malar J 2009, 8:204.
39. Nsimba SE, Massele AY, Eriksen J, Gustafsson LL, Tomson G, Warsame M:
Case management of malaria in under-fives at primary health care
facilities in a Tanzanian district. Trop Med Int Health 2002, 7:201-209.
40. Checchi F, Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E,
Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor WR,
Guthmann JP: Supervised versus unsupervised antimalarial treatment
with six-dose artemether-lumefantrine: pharmacokinetic and dosagerelated findings from a clinical trial in Uganda. Malar J 2006, 5:59.
41. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and
pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
Clin Pharmacokinet 1999, 37:105-125.
42. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and
pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
Clin Pharmacokinet 1999, 37:105-125.
43. Borrmann S, Sallas WM, Machevo S, Gonzalez R, Bjorkman A,
Martensson A, Hamel M, Juma E, Peshu J, Ogutu B, Djimde A,
D’Alessandro U, Marrast AC, Lefevre G, Kern SE: The effect of food
consumption on lumefantrine bioavailability in African children
receiving artemether-lumefantrine crushed or dispersible tablets
(Coartem) for acute uncomplicated Plasmodium falciparum malaria.
Trop Med Int Health 2010, 15:434-441.
44. Hastings IM, Watkins WM, White NJ: The evolution of drug-resistant
malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B
Biol Sci 2002, 357:505-519.
45. Nzila AM, Nduati E, Mberu EK, Hopkins Sibley C, Monks SA, Winstanley PA,
Watkins WM: Molecular evidence of greater selective pressure for drug
resistance exerted by the long-acting antifolate Pyrimethamine/
Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone
on Kenyan Plasmodium falciparum. J Infect Dis 2000, 181:2023-2028.
46. Sisowath C, Petersen I, Veiga MI, Martensson A, Premji Z, Bjorkman A,
Fidock DA, Gil JP: In vivo selection of Plasmodium falciparum
parasites carrying the chloroquine-susceptible pfcrt K76 allele after
treatment with artemether-lumefantrine in Africa. J Infect Dis 2009,
199:750-757.
47. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A,
Gil JP: In vivo selection of Plasmodium falciparum pfmdr1 86N coding
alleles by artemether-lumefantrine (Coartem). J Infect Dis 2005,
191:1014-1017.
48. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G: Selection
of Plasmodium falciparum pfmdr1 alleles following therapy with
artemether-lumefantrine in an area of Uganda where malaria is highly
endemic. Antimicrob Agents Chemother 2006, 50:1893-1895.
49. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK,
Sutherland CJ, Hallett RL: Amodiaquine and artemether-lumefantrine
select distinct alleles of the Plasmodium falciparum mdr1 gene in
Tanzanian children treated for uncomplicated malaria. Antimicrob Agents
Chemother 2007, 51:991-997.
50. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O’Neil M,
Milhous W, Wirth DF, Oduola AM: Selection of Plasmodium falciparum
multidrug resistance gene 1 alleles in asexual stages and gametocytes

Ngasala et al. Malaria Journal 2011, 10:64
http://www.malariajournal.com/content/10/1/64

Page 10 of 10

by artemether-lumefantrine in Nigerian children with uncomplicated
falciparum malaria. Antimicrob Agents Chemother 2009, 53:888-895.
51. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K,
Borrmann S, Nzila A: In vitro activities of piperaquine, lumefantrine, and
dihydroartemisinin in Kenyan Plasmodium falciparum isolates and
polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 2009,
53:5069-5073.
doi:10.1186/1475-2875-10-64
Cite this article as: Ngasala et al.: Effectiveness of artemetherlumefantrine provided by community health workers in under-five
children with uncomplicated malaria in rural Tanzania: an open label
prospective study. Malaria Journal 2011 10:64.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

